Radiopharmaceuticals and Tracers

News | Radiopharmaceuticals and Tracers | January 17, 2017

NorthStar Medical Technologies LLC has received additional matching funds from the U.S. Department of Energy’s ...

metastatic colorectal cancer, mCRC, Sirtex, NCCN guidelines, Y-90 microspheres
News | Radiation Therapy | January 03, 2017

Sirtex Medical Limited announced in December that SIR-Spheres Y-90 resin microspheres have been included as a...

SNMMI Develops USP Recommendations for Compounded Sterile Radiopharmaceuticals
News | December 28, 2016

December 28, 2016 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has developed United States...

prostate, CT scan
News | Prostate Cancer | December 22, 2016

Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on cancer diagnostics...

News | Prostate Cancer | December 14, 2016

Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on small molecules that...

News | Nuclear Imaging | December 12, 2016

Molecular Targeting Technologies, Inc. (MTTI) announces that response of colorectal cancer to treatment can be...

Alzheimer's disease, early diagnosis, PET scans, imaging compound, Fluselenamyl

Researchers at Washington University School of Medicine in St. Louis have developed a chemical compound that detects the Alzheimer’s protein amyloid beta better than current FDA-approved agents. The compound potentially may be used in brain scans to identify people in the earliest stages of Alzheimer’s disease. In the image, the compound has passed from the bloodstream of a living mouse into its brain, where it is detected by a positron emission tomography (PET) scan. Arrows indicate clumps of amyloid beta. Credit Ping Yan and Jin-Moo Lee.

News | Radiopharmaceuticals and Tracers | November 02, 2016

November 2, 2016 — By the time unambiguous signs of memory loss and cognitive decline appear in people with...

NAS report, National Academies of Sciences Engineering and Medicine, Mo-99 production, highly enriched uranium, HEU, SNMMI
News | Radiopharmaceuticals and Tracers | October 28, 2016

The National Academies of Sciences, Engineering, and Medicine (NAS) have released a report on the state of...

Axumin, fluciclovine F-18, PET agent, Phase 3 study, recurrent prostate cancer detection, Blue Earth Diagnostics
News | Prostate Cancer | October 25, 2016

Blue Earth Diagnostics Ltd. announced the peer-reviewed publication of results from a Phase 3 clinical trial of...

Lantheus, flurpiridaz F-18, myocardial perfusion imaging, MPI, cardiac stress testing, ASNC 2016
News | Radiopharmaceuticals and Tracers | October 17, 2016

Lantheus Holdings Inc. announced in late September that sub-analysis data from the first Phase 3 study of...

Alzheimer's, ADNI3 study, Alzheimer's Disease Neuroimaging Initiative, NIH grant, MRI, PET, biomarkers
Feature | Neuro Imaging | September 09, 2016

September 9, 2016 — The Alzheimer’s Disease...

Axumin, fluciclovine F-18 injection, first injection, Northside Hospital Atlanta
News | Radiopharmaceuticals and Tracers | September 07, 2016

September 7, 2016 — Blue Earth Diagnostics announced that the first post-U.S.

News | Radiopharmaceuticals and Tracers | September 06, 2016

Navidea Biopharmaceuticals Inc. announced that it has executed a Letter of Intent (LOI) with Cardinal Health for the...

ASNC, SNMMI, position statement, myocardial perfusion PET, coronary artery disease
News | PET Imaging | September 01, 2016

September 1, 2016 — The American Society for Nuclear Cardiology (ASNC) and the Society of...

Lantheus, Xenon 133 gas, radiopharmaceuticals, IRE, Institute for Radioelements Belgium
News | Radiopharmaceuticals and Tracers | July 12, 2016

Lantheus Holdings Inc., the parent company of Lantheus Medical Imaging Inc. (LMI), announced the first commercial...

Cell>Point, license agreement, China, United Eastern Pharmaceutical, Oncardia imaging agent
News | Radiopharmaceuticals and Tracers | July 07, 2016

July 7, 2016 — Cell>Point announced in mid-June it has entered into an...

Navidea, Lymphoseek injection, breast cancer detction, scintigraphy, SNMMI 2016
News | Radiopharmaceuticals and Tracers | July 06, 2016

Navidea Biopharmaceuticals Inc. announced results from three investigator-initiated studies of the Lymphoseek...

blood test, PRRT, neuroendocrine tumors, NETs, somatostatin receptor imaging, SRI, SNMMI 2016 study

NET circulating transcript and chromogranin A (CgA) levels in responders and non-responders. a) Transcripts were significantly reduced at 6-month follow-up compared to pre-treatment values. Non-responders (NR) exhibited significantly elevated levels at 6 months (FUP_6m). This was also significantly higher than in responders (R). b) A significant alteration was noted only for CgA in non-responders (NR) at 6 months. c) Pre-PRRT: NET transcript scores were elevated in 94 percent and CgA in 57 percent. d) Responders: NET transcripts decreased in 88 percent of responders (no change in 12 percent). CgA was unchanged in 47 percent, decreased in 21 percent and was elevated in 32 percent. e) Non-Responders: NET transcripts increased in 90 percent (no change in 10 percent). CgA was unchanged in 33 percent, decreased in 40 percent and was elevated in 27 percent. For NET transcripts, no falsely decreased or increased values occurred in responders or non-responders, respectively. Credit: LuGenIum Consortium for Independent Research & Wren Laboratories

News | Oncology Diagnostics | June 23, 2016

Malignant neuroendocrine tumors (NETs) are relatively rare, notoriously difficult to treat, and associated with poor...

PET, neuroinflammation, multiple sclerosis, MS, Adam Rosenberg, SNMMI 2016

A. Increased F-18 TZ3504 uptake was observed in the inflamed lumbar spinal cord of EAE-treated animals in the rat model of MS compared to sham control rats. Representative sagittal, coronal and transverse views of the thoracic and lumbar spine are shown. B. The time activity curve of F-18 TZ3504 uptake in the lumbar spinal cord was significantly higher for the first 30 minutes in EAE-treated rats. C. F-18 TZ3504 was able to cross the blood brain barrier and showed homogeneous distribution in the brain of a healthy nonhuman primate. Image Credit:  Mallinckrodt Institute of Radiology at the Washington University School of Medicine, St. Louis, Mo.

News | PET Imaging | June 23, 2016

The triggers of autoimmune inflammation in multiple sclerosis (MS) have eluded scientists for many years, but...

neuroendocrine tumors, NET, radiotherapy dose, PET, SPECT, SNMMI 2016

Comparison of Ga-68-DOTATOC PET/CT with Y-90 DOTATOC PET/CT. Although the positron associated with Y-90 is rarely emitted, there is still sufficient signal to acquire a quantitative PET/CT image of Y-90 DOTATOC after a therapeutic administration. The white arrows indicate kidneys and the yellow arrows tumor. Credit: University of Iowa

News | Nuclear Imaging | June 23, 2016

Aggressive neuroendocrine cancer is something of a dark horse — a rare, elusive and persevering force linked to...

Overlay Init